(Q35690167)

English

Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy

scientific article published on January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

metastatic breast cancer

1 reference

based on heuristic

inferred from title

3

object named as

Greg L Plosker

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Monique P Curran

2

object named as

Monique P Curran

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1

object named as

Kate McKeage

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

64

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

633-648

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiestrogen ICI 182,780 decreases proliferation of insulin-like growth factor I (IGF-I)-treated MCF-7 cells without inhibiting IGF-I signaling

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant (Faslodex): current status in the therapy of breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antagonism of oestrogen action in human breast and endometrial cells in vitro: potential novel antitumour agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The estrogen antagonist ICI 182,780 reduces cancellous bone volume in female rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of apoptosis in mammary gland by a pure anti-estrogen ICI 182780.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine therapy of advanced disease: analysis and implications of the existing data.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Steroidal pure antioestrogens

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen-accelerated bone maturation in mice is not attenuated by Faslodex, an estrogen receptor blocker

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pure antiestrogen ICI 182780 is more effective in the induction of apoptosis and down regulation of BCL-2 than tamoxifen in MCF-7 cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiuterotrophic effects of the pure antioestrogen ICI 182,780 in adult female monkeys (Macaca nemestrina): quantitative magnetic resonance imaging

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Action of "pure" antiestrogens in inhibiting estrogen receptor action

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

17 beta-estradiol increases calcium content in fetal mouse parietal bones cultured in serum-free medium only at physiological concentrations

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison between novel steroid-like and conventional nonsteroidal antioestrogens in inhibiting oestradiol- and IGF-I-induced proliferation of human breast cancer-derived cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pure anti-oestrogen ICI 182,780 (Faslodex) activates large conductance Ca(2+)-activated K(+) channels in smooth muscle.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mechanism of ICI 164,384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine therapy in the treatment of metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of insulin-like growth factor I receptor expression by the pure antiestrogen ICI 182780

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780.

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A potent specific pure antiestrogen with clinical potential

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/15018596

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/00003495-200464060-00009

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35690167&oldid=2197629860"